|
Jul 1
|
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
|
|
Jun 30
|
Strong week for NovoCure (NASDAQ:NVCR) shareholders doesn't alleviate pain of three-year loss
|
|
Jun 30
|
NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?
|
|
Jun 30
|
Novocure to Report Second Quarter 2025 Financial Results
|
|
Jun 18
|
What Makes NovoCure (NVCR) a New Buy Stock
|
|
Jun 6
|
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial
|
|
Jun 2
|
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial
|
|
May 31
|
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
|
|
May 28
|
1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street
|
|
May 27
|
Novocure Announces Upcoming Investor Events
|
|
Feb 28
|
NovoCure Full Year 2024 Earnings: EPS Misses Expectations
|
|
Feb 28
|
NovoCure Ltd (NVCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ...
|
|
Feb 27
|
NovoCure (NVCR) Q4 2024 Earnings Call Transcript
|
|
Feb 27
|
NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say
|
|
Feb 27
|
NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates
|
|
Feb 27
|
NovoCure: Q4 Earnings Snapshot
|
|
Feb 27
|
Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
|
|
Feb 20
|
NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
|
Feb 20
|
Luxury hotels group Firmdale has sold 20% stake to Swedish pharma tycoon
|
|
Jan 30
|
Jim Cramer on NovoCure Limited (NVCR): ‘I Have Watched Them For Years And Years And They’re Not Making Money’
|